ABL Bio Wins 'Most Promising Biopharmaceutical Pipeline' Award

ABL Bio (ABL Bio) announced on the 16th that it won the Most Promising Biopharmaceutical Pipeline award at the ‘Korea Pharmaceutical Bio Excellence Awards 2024’ hosted by IMAPAC, a company specializing in pharmaceutical and bio industry events. The award ceremony was held on the 13th in Songdo, Incheon, as part of the ‘13th Biologics Manufacturing Korea 2024 and 6th Vaccine World East Asia 2024’ conference program.

[Photo by ABL Bio]

ABL Bio is developing immuno-oncology drugs applying the 4-1BB-based bispecific antibody platform ‘Grabody-T’ and treatments for degenerative brain diseases using the blood-brain barrier (BBB) shuttle platform ‘Grabody-B’. Development is underway for phase 1 clinical stage immuno-oncology drugs ABL503, ABL111, ABL103, and ABL105. In 2022, it signed a joint development and technology transfer agreement with Sanofi for the Parkinson’s disease treatment ABL301, with a maximum contract value of $1.06 billion (approximately 1 trillion KRW). Recently, the company has focused on developing bispecific antibody ADCs, a next-generation modality that can improve the safety and efficacy of existing monoclonal antibody antibody-drug conjugates (ADCs), aiming to submit Investigational New Drug (IND) applications for at least three pipelines by 2025.

Lee Sang-hoon, CEO of ABL Bio, said, “This was an opportunity to once again demonstrate the technological capabilities of the bispecific antibody and ADC pipelines that ABL Bio is developing. In addition to the existing bispecific antibody immuno-oncology drugs and degenerative brain disease treatments, we will accelerate the development of bispecific antibody ADCs as a new future growth engine to preoccupy the still early-stage global bispecific antibody ADC market.”